Medical devices, healthcare technology and the business of care
PMA approval · P010007

IMMULITE/IMMULITE 1000 AFP AND IMMULITE 2000/IMMULITE 2500 AFP

Siemens Healthcare Diagnostics, Inc. · Decision date Nov 9, 2001

MEDTECHLEDGER EXPLANATIONP010007

What did the FDA approve?

FDA approved the IMMULITE AFP for the IMMULITE analyzer and IMMULITE 2000 AFP for the IMMULITE 2000 analyzer on November 9, 2001. The devices quantitatively measure alpha-fetoprotein in serum for serial monitoring of patients with nonseminomatous testicular cancer, or in maternal serum and amniotic fluid at gestational weeks 15 through 20, with ultrasonography or amniography, to aid detection of fetal open neural tube defects.

The decision is an original PMA approval, not a supplement. The statement describes the intended diagnostic uses but does not provide independent evidence of safety or clinical effectiveness. Specific information absent from the record includes any clinical trial data, performance metrics, or labeling details beyond the stated indications.

FDA approval order statement

APPROVAL FOR IMMULITE AFP FOR USE WITH THE IMMULITE ANALYZER AND IMMULITE 2000 AFP FOR USE WITH THE IMMULITE 2000 ANALYZER. THESE DEVICES ARE INDICATED FOR IN VITRO DIAGNOSTIC USE FOR THE QUANTITATIVE MEASUREMENT OF ALPHA-FETOPROTEIN (AFP) IN EITHER OF TWO CONTEXTS: A) SERIAL MEASUREMENTS IN HUMAN SERUM TO AID IN THE MANAGEMENT OF PATIENTS WITH NONSEMINOMATOUS TESTICULAR CANCER: OR B) MEASUREMENT IN MATERNAL SERUM AND AMNIOTIC FLUID DURING GESTATIONAL WEEKS 15 THROUGH 20 - USED IN CONJUNCTION WITH ULTRASONOGRAPHY OR AMNIOGRAPHY - TO AID IN DETECTION OF FETAL OPEN NEURAL TUBE DEFECTS.
Regulatory pathway
Original PMA
Clinical specialty
Immunology
Decision date
Nov 9, 2001

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P010007
Regulatory pathway
Premarket approval application
Product code
LOK
Decision code
APPR
Decision date
Nov 9, 2001
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: KIT, TEST, ALPHA-FETOPROTEIN FOR NEURAL TUBE DEFECTS.

Product code
LOK
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P010007 received

    Application receipt date recorded by FDA.

  2. P010007 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P010007. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P010007

Product / regulatory recordCompanyPathwayDecision dateSource
IMMULITE 2000 AFPP010007/S024
Siemens Healthcare Diagnostics, Inc.PMA supplementOct 30, 2025FDA
IMMULITE 2000 AFPP010007/S025
Siemens Healthcare Diagnostics, Inc.PMA supplementApr 21, 2026FDA
IMMULITE 2000 AFPP010007/S026
Siemens Healthcare Diagnostics, Inc.PMA supplementJul 27, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementAug 20, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementSep 22, 2026FDA

Explore the linked device profile

Other records with product code LOK

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT LABORATORIESPMA supplementMay 11, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementMay 11, 2026FDA
ABBOTT LABORATORIESPMA supplementFeb 12, 2026FDA
BECKMAN COULTER, INC.PMA supplementNov 3, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Siemens Healthcare Diagnostics, Inc.

Headquarters
Not reported
FDA applicant address
511 Benedict Ave., Tarrytown, NY, 10591

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records